Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Immunoscintigraphy of recurrences of gynecologic carcinomas

Journal Article · · J. Nucl. Med.; (United States)
OSTI ID:5519823
In a first, retrospective study, 15 patients with known ovarian carcinoma were injected with /sup 131/I-OC 125 F(ab')2 monoclonal antibody (MAb). The sensitivity of immunoscintigraphy based on the number of the tumor sites was 67% (12/18). In a second, prospective study, 29 patients with gynecologic carcinoma were injected with /sup 131/I-OC 125 F(ab')2 (24) or /sup 131/I-19-9 F(ab')2 (5) MAbs according to the histologic type. Based on the number of tested anatomic sites, sensitivity was 72% and specificity 86%. In two patients injected with both /sup 131/I-OC-125 F(ab')2 and /sup 125/I-NS F(ab')2 (nonspecific immunoglobulin) 1 and 4 days before tumor resection, tumor uptake of the specific antibody was 2.2 and 4.5 times greater than that of NS. Immunoscintigraphic results were complementary with those of ultrasonography and computed tomography. Finally, in one patient injected successively with /sup 131/I-OC 125 F(ab')2 and /sup 111/In-DTPA-OC 125 F(ab')2, the recurrent tumor was visualized with both radionuclides, with /sup 111/In providing better abdominal tumor contrast but causing much greater liver radioactivity than /sup 131/I.
Research Organization:
UER de Medecine, Nantes, France
OSTI ID:
5519823
Journal Information:
J. Nucl. Med.; (United States), Journal Name: J. Nucl. Med.; (United States) Vol. 28:12; ISSN JNMEA
Country of Publication:
United States
Language:
English